Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japanese Drug Makers Encounter High Prices For Foreign M&As

This article was originally published in PharmAsia News

Executive Summary

Despite the current global economy, Japanese drug makers seeking acquisitions abroad continue to face demands for high prices for buyout proposals. Japanese pharmas, still cash-rich, seek access to foreign markets to make up for declining sales at home where the government is pressing for purchases of more generics to replace branded drugs. Together, Japanese drug makers have spent more than $20 billion the past year on foreign acquisitions. Would-be sellers, though, appear aware their properties are valuable to the Japanese. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC067178

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel